• Orthocell expands clinical presence to Singapore
  • First patient in Singapore undergoes Ortho-ACIâ„¢ cell therapy for damaged articular cartilage of the knee

PERTH, Australia--(Antara/BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited is pleased to announce its regenerative cell therapy treatment, Ortho-ACITM, has been applied to its first patient in Singapore.

Singapore is the latest international market Orthocell has expanded Ortho-ACITM into, following its successful entry to Hong Kong earlier this year where the therapy was used on patients with articular cartilage damage within the knee joint.

Ortho-ACITM involves taking cartilage cells from a patient via a biopsy, expanding the cell volume in a Therapeutic Goods Authority (TGA)-licensed laboratory (Lic # MI-19052008-LI-002420-11) and then implanting these cells surgically back into the area of cartilage damage to regenerate the lost tissue.

Managing Director Paul Anderson said, “The availability of this technology puts Australia and the region at the very forefront of the provision of a sophisticated, high quality and cost effective regenerative treatment to help people with painful and difficult to treat cartilage injuries that often lead to osteoarthritis if left untreated.

“Singapore is the latest country where Ortho-ACI™ has been used as we continue to expand our reach into the region from our state-of-the-art production facility in Australia.”

Leading Singaporean orthopaedic surgeon Dr Derrick Oh completed the Ortho-ACITM implantation at Gleneagles Hospital, Singapore. Ortho-ACIâ„¢ is a cellular therapy for the regeneration of articular cartilage of the joints, offering a high quality, cost effective, customized approach and is currently being used by orthopaedic key opinion leaders in Australia, New Zealand, Hong Kong and Singapore.

The global regenerative medicine market has been forecast to reach $US67.6 billion in 2020, from $US16.4 billion in 2014, with the Asia-Pacific region expected to be the fastest growing region1.

1. http://www.prnewswire.co.uk/news-releases/regenerative-medicine-market-is-expected-to-reach-676-billion-global-by-2020-265200791.html

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151117007098/en/

Contacts

General enquiries
Orthocell Limited
Paul Anderson, (08) 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor relations
Buchan Consulting
Ben Walsh, + 61 468 422 865
bwalsh@buchanwe.com.au
or
Media enquiries
Buchan Consulting
Gavin Lower, (03) 8866 1215 / 0414 796 726
glower@buchanwe.com.au

Source: Orthocell Limited

Reporter: PR Wire
Editor: PR Wire
Copyright © ANTARA 2015